{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T09:50:32Z","timestamp":1775382632421,"version":"3.50.1"},"reference-count":92,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,5,4]]},"DOI":"10.1080\/13543776.2022.2045947","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T23:01:05Z","timestamp":1645743665000},"page":"507-522","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Menin-MLL protein-protein interaction inhibitors: a patent review (2014\u20132021)"],"prefix":"10.1080","volume":"32","author":[{"given":"Huanrong","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, 710061, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"San-Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, 710061, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, 710061, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Hebei Chemical & Pharmaceutical College, Shijiazhuang 050000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, 710061, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhang","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, 710061, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2253"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124032"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060837"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.2.617-628.2004"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550079"},{"issue":"19","key":"cit0006","volume":"74","author":"Cierpicki T","year":"2014","journal-title":"Cancer Res"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3602"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2369"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.09.025"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1805035"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1309\/RX27R8GJQM330C22"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.144"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.30"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2010.07609.x"},{"key":"cit0015","first-page":"857","volume":"36","author":"Lai Y","year":"2014","journal-title":"Chin. J. Cell Biol"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124032"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2013.05.005"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201200007"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.169"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3417"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.05.003"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-1664-8_5"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.13.214"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510347103"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122721"},{"issue":"3","key":"cit0026","first-page":"341","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0723-0"},{"key":"cit0028","volume-title":"AACR Virtual Annual Meeting I, New Drugs on the Horizon Session 1","author":"McGeehan J","year":"2020"},{"key":"cit0029","unstructured":"SNDX-5613 briefing document for the 18 June 2020 oncologic drugs advisory committee pediatric subcommittee. 2020;6(18):16\u201326."},{"key":"cit0030","unstructured":"Syndax announces positive interim data demonstrating robust clinical activity in phase 1 portion of the AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias. News release. Syndax Pharmaceuticals Inc. 2021 Apr 20. Accessed 2021 Sept 19."},{"key":"cit0031","unstructured":"National Institutes of Health. (n.d.). ChemIDplus - 2134675-36-6 - BGGALFIXXQOTPY-NRFANRHFSA-N - KO-539 - similar structures search, synonyms, formulas, resource links, and other chemical information. U.S. National Library of Medicine. Cited 2021 Oct 11, from https:\/\/chem.nlm.nih.gov\/chemidplus\/rn\/2134675-36-6."},{"key":"cit0032","unstructured":"Kura Oncology\u2019s menin-MLL inhibitor KO-539 receives orphan drug designation from FDA for Treatment of acute myeloid leukemia. News release. Kura Oncology. 2019 Jul 24."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134942"},{"key":"cit0034","unstructured":"Kura oncology presents first clinical data for menin inhibitor ko-539 at American society of hematology annual meeting. News release. Kura Oncology Inc. 2020 Dec 5. Accessed 2021 Sept 19."},{"key":"cit0035","volume-title":"AACR Virtual Annual Meeting","author":"Numata M","year":"2021"},{"key":"cit0036","unstructured":"A study of JNJ-75276617 in participants with acute leukemia. Full Text View - ClinicalTrials.gov. (n.d.). Cited 202 Dec 28. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04811560"},{"key":"cit0037","unstructured":"Rinde M. Moving curative therapies forward in hematologic malignancies. OncLive. Cited 2021 Dec 28. https:\/\/www.onclive.com\/view\/moving-curative-therapies-forward-in-hematologic-malignancies"},{"key":"cit0038","unstructured":"Biomea fusion announces FDA clearance of investigational new drug application for irreversible menin inhibitor BMF-219. News release. Biomea Fusion Inc. 2021 Sep 16; Accessed 2021 Sept 8."},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00872"},{"key":"cit0040","unstructured":"Vitae Pharmaceuticals Inc. Inhibitors of the Menin-MLL interaction. WO2017214367. 2017."},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.11.001"},{"key":"cit0042","unstructured":"Sumitomo Dainippon Pharma Co Ltd. Optically active azabicyclic derivative. WO2020045334. 2020."},{"key":"cit0043","unstructured":"The Regents of the University of Michigan. Compositions comprising thienopyrimdine and Thienopyridine compounds and Methods of use thereof. US20140275070. 2014."},{"key":"cit0044","unstructured":"The Regents of the University of Michigan. Compositions comprising thienopyrimdine and Thienopyridine compounds and Methods of use thereof. US20160046647. 2016."},{"key":"cit0045","unstructured":"The Regents of the University of Michigan. Thienopyrimidine and thienopyridine compounds and methods of use thereof. WO2016040330. 2016."},{"key":"cit0046","unstructured":"Kura Oncology Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins. WO2016195776. 2016."},{"key":"cit0047","unstructured":"Vitae Pharmaceuticals, Inc. Inhibitors of the Menin-MLL interaction. WO2017112768. 2017."},{"key":"cit0048","unstructured":"Memorial Sloan-Kettering Cancer Center. Targeting chromatin regulators inhibits leukemogenic gene expression n npm1mutant leukemia. WO2017132398. 2017."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.016"},{"key":"cit0050","unstructured":"Kura Oncology Inc. Bridged bicyclic inhibitors of Menin-MLL and methods of use. WO2017161002. 2017."},{"key":"cit0051","unstructured":"Kura Oncology Inc. Substituted inhibitors of Menin-MLL and methods of use. WO2017161028. 2017."},{"key":"cit0052","author":"Kura Oncology Inc","year":"2018","journal-title":"WO2018175746"},{"key":"cit0053","unstructured":"Janssen Pharmaceutica NV. Fused bicyclic inhibitors of Menin-MLL interaction. WO2018050684. 2018."},{"key":"cit0054","unstructured":"Janssen Pharmaceutica NV. Spiro bicyclic inhibitors of Menin-MLL interaction. WO2018050686. 2018."},{"key":"cit0055","unstructured":"Bayer Pharma AG. 2,7\u2013diazaspiro [4.4] nonanes. WO2018024602. 2018."},{"key":"cit0056","unstructured":"Kura Oncology Inc. Methods of promoting beta cell proliferation. WO2018106818. 2018."},{"key":"cit0057","unstructured":"Janssen Pharmaceutica NV. AZEPANE inhibitors of Menin-MLL interaction. WO2018109088. 2018."},{"key":"cit0058","unstructured":"Shanghai Institute of Pharmaceutical Sciences. Chinese Academy of Sciences. A class of thieno[3,2-d] pyrimidine derivatives containing a cyclopropylamine structure, their preparation methods and uses. CN201810169262. 2018."},{"key":"cit0059","unstructured":"Shanghai Institute of Pharmaceutical Sciences. Chinese academy of sciences. A class of thieno[3,2-d] pyrimidine derivatives, their preparation methods and uses. CN201810169265. 2018."},{"key":"cit0060","unstructured":"Kura Oncology Inc. Substituted inhibitors of Menin-MLL and methods of use. WO2019060365. 2019."},{"key":"cit0061","author":"Janssen Pharmaceutica NV.","year":"2019","journal-title":"WO2019120209"},{"key":"cit0062","unstructured":"Kura Oncology Inc. Treatment of hematological malignancies with inhibitors of Menin. WO2020060927. 2020."},{"key":"cit0063","unstructured":"Sumitomo Dainippon Pharma Co Ltd. Optically active crosslinked cyclic secondary amine derivative. WO2019189732. 2019."},{"key":"cit0064","author":"Sumitomo Dainippon Pharma Co Ltd","year":"2020","journal-title":"WO2020032105"},{"key":"cit0065","author":"Daiichi Sankyo Company Limited JP","year":"2020","journal-title":"WO202011662"},{"key":"cit0066","unstructured":"The regents of the University of Michigan, Vanderbilt University. Menin-MLL inhibitors and methods of use thereof. US20140371239. 2014."},{"key":"cit0067","unstructured":"The regents of the University of Michigan, Vanderbilt University. Menin-MLL inhibitors and methods of use thereof. WO2014200479. 2014."},{"key":"cit0068","unstructured":"The Regents of the University of Michigan. Piperidine compounds as covalent Menin inhibitors. WO2019191526. 2019."},{"key":"cit0069","author":"The Regents of the University of Michigan, Agios Pharmaceuticals Inc","year":"2020","journal-title":"WO2020072391"},{"key":"cit0070","unstructured":"Agios Pharmaceuticals Inc. The Regents of The University of Michigan. Piperidine compounds as Menin inhibitors. WO2021067215. 2021."},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201711828"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00547"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00789"},{"key":"cit0074","author":"Agios Pharmaceuticals Inc","year":"2021","journal-title":"WO2021207310"},{"key":"cit0075","author":"Agios Pharmaceuticals Inc","year":"2021","journal-title":"WO2021204156"},{"key":"cit0076","author":"The Trustees of the University of Pennsylvania","year":"2015","journal-title":"WO2015191701"},{"key":"cit0077","author":"Vitae Pharmaceuticals, Inc","year":"2018","journal-title":"WO2018053267"},{"key":"cit0078","author":"Vitae Pharmaceuticals, Inc","year":"2019","journal-title":"US20190202830"},{"key":"cit0079","author":"Sumitomo Dainippon Pharma Co., Ltd","year":"2021","journal-title":"WO2021060453"},{"key":"cit0080","author":"Biomea Fusion LLC","year":"2020","journal-title":"WO2020142557"},{"key":"cit0081","author":"Biomea Fusion LLC","year":"2020","journal-title":"WO2020142559"},{"key":"cit0082","author":"Janssen Pharmaceutica NV","year":"2021","journal-title":"WO2021121327"},{"key":"cit0083","author":"Kura Oncology Inc","year":"2018","journal-title":"WO2018226976"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00021"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112748"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1021\/jm3015298"},{"issue":"13","key":"cit0087","volume":"81","author":"Numata M","year":"2021","journal-title":"Cancer Res."},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005037"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429274"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.773"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134942"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201711828"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2045947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T13:34:07Z","timestamp":1651152847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2045947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,4]]}},"alternative-id":["10.1080\/13543776.2022.2045947"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2045947","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}